Efficacy of gene therapy for Wiskott-Aldrich syndrome using a WAS promoter/cDNA-containing lentiviral vector and nonlethal irradiation

Human Gene Therapy

Volumn 17, Issue 3, 2006, Pages 303-313

  Dupré, Loëc ^a   Marangoni, Francesco ^a,b   Scaramuzza, Samantha ^a   Trifari, Sara ^a   Hernandez, Raisa Jofra ^a   Aiuti, Alessandro ^a   Naldini, Luigi ^a,b   Roncarolo, Maria Grazia ^a,b  

^a SAN RAFFAELE SCIENTIFIC INSTITUTE   (Italy)

^b VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CD11B ANTIGEN; CD3 ANTIGEN; CD45 ANTIGEN; COMPLEMENTARY DNA; F ACTIN; INTERLEUKIN 2; MONOCLONAL ANTIBODY CD3; T LYMPHOCYTE RECEPTOR; THY 1 ANTIGEN; WISKOTT ALDRICH SYNDROME PROTEIN;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTOIMMUNE DISEASE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; AUTOPSY; B LYMPHOCYTE; BLEEDING; BLOOD ANALYSIS; BONE MARROW CELL; CELL PROLIFERATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; GENE EXPRESSION; GENE LOCATION; GENE THERAPY; GENE TRANSFER; GENETIC TRANSDUCTION; HUMAN; HUMAN CELL; IMMUNE DEFICIENCY; INFECTION; IRRADIATION; LENTIVIRUS VECTOR; LYMPHOMA; MALE; MOUSE; NONHUMAN; PROMOTER REGION; PROTEIN POLYMERIZATION; SYNAPSE; T LYMPHOCYTE; THROMBOCYTE; TISSUE SPECIFICITY; TREATMENT OUTCOME; WISKOTT ALDRICH SYNDROME; X CHROMOSOME LINKED DISORDER;

ACTINS; ANIMALS; B-LYMPHOCYTES; BLOTTING, WESTERN; CELL PROLIFERATION; DNA, COMPLEMENTARY; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; GENE THERAPY; GENETIC VECTORS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INTERLEUKIN-2; LENTIVIRUS; MICE; MICE, INBRED C57BL; PROMOTER REGIONS (GENETICS); REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; T-LYMPHOCYTES; TRANSDUCTION, GENETIC; TRANSPLANTATION, AUTOLOGOUS; WISKOTT-ALDRICH SYNDROME; WISKOTT-ALDRICH SYNDROME PROTEIN;

ANIMALIA; LENTIVIRUS;

EID: 33645458063     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/hum.2006.17.303     Document Type: Article

References (37)

1. ABDUL-MANAN, N., AGHAZADEH, B., LIU, G.A., MAJUMDAR, A., OUEFELLI, O., SIMINOVITCH, K.A., and ROSEN, M. (1999). Structure of Cdc42 in complex with the GTPase-binding domain of the Wiskott-Aldrich syndrome protein. Nature 399, 379-383.
2. AIUTI, A., SLAVIN, S., AKER, M., FICARA, F., DEOLA, S., MORTELLARO, A., MORECKI, S., ANDOLFI, G., TABUCCHI, A., CARLUCCI, F., MARINELLO, E., CATTANEO, F., VAI, S., SERVIDA, P., MINIERO, R., RONCAROLO, M.G., and BORDIGNON, C. (2002). Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning. Science 296, 2410-2413.
3. ALDRICH, R., STEINBERG, A., and CAMPBELL, D. (1954). Pedigree demonstrating a sex-linked recessive condition characterized by draining ears, eczematoid dermatitis and bloody diarrhea. Pediatrics 13, 133-139.
4. ANDREANSKY, S., LIU, H., TURNER, S., McCULLERS, J.A., LANG, R., RUTSCHMAN, R., DOHERTY, P.C., MURRAY, P.J., NIENHUIS, A.W., and STROM, T.S. (2005). WASP- mice exhibit defective immune responses to influenza A virus, Streptococcus pneumoniae, and Mycobacterium bovis BCG. Exp. Hematol. 33, 443-451.
5. ANTOINE, C., MULLER, S., CANT, A., CAVAZZANA-CALVO, M., VEYS, P., VOSSEN, J., FASTH, A., HEILMANN, C., WULFFRAAT, N., SEGER, R., BLANCHE, S., FRIEDRICH, W., ABINUN, M., DAVIES, G., BREDIUS, R., SCHULZ, A., LANDAIS, P., and FISCHER, A. (2003). Long-term survival and transplantation of haemopoietic stem cells for immunodeficiencies: Report of the European experience 1968-99. Lancet 361, 553-560.
6. BADOLATO, R., SOZZANI, S., MALACARNE, F., BRESCIANI, S., FIORINI, M., BORSATTI, A., ALBERTINI, A., MANTOVANI, A., UGAZIO, A.C., and NOTARANGELO, L.D. (1998). Monocytes from Wiskott-Aldrich patients display reduced chemotaxis and lack of cell polarization in response to monocyte chemoattractant protein-1 and formyl-methionyl-leucyl-phenylalanine. J. Immunol. 161, 1026-1033.
7. BADOUR, K., ZHANG, J., SHI, F., McGAVIN, M.K., RAMPERSAD, V., HARDY, L.A., FIELD, D., and SIMINOVITCH, K.A. (2003). The Wiskott-Aldrich syndrome protein acts downstream of CD2 and the CD2AP and PSTPIP1 adaptors to promote formation of the immunological synapse. Immunity 18, 141-154.
8. BINKS, M., JONES, G., BRICKELL, P., KINNON, C., KATZ, D., and THRASHER, A.J. (1998). Intrinsic dendritic cell abnormalities in Wiskott-Aldrich syndrome. Eur. J. Immunol. 28, 3259-3267.
9. BORG, C., JALIL, A., LADERACH, D., MARUYAMA, K., WAKASUGI, H., CHARRIER, S., RYFFEL, B., CAMBI, A., FIGDOR, C., VAINCHENKER, W., GALY, A., CAIGNARD, A., and ZITVOGEL, L. (2004). NK cell activation by dendritic cells (DCs) requires the formation of a synapse leading to IL-12 polarization in DCs. Blood 104, 3267-3275.
10. BURNS, S., CORY, G.O., VAINCHENKER, W., and THRASHER, A.J. (2004). Mechanisms of WASp-mediated hematologic and immunologic disease. Blood 104, 3454-3462.
11. CHARRIER, S., STOCKHOLM, D., SEYE, K., OPOLON, P., TAVEAU, M., GROSS, D.A., BUCHER-LAURENT, S., DELENDA, C., VAINCHENKER, W., DANOS, O., and GALY, A. (2005). A lentiviral vector encoding the human Wiskott-Aldrich syndrome protein corrects immune and cytoskeletal defects in WASP knockout mice. Gene Ther. 12, 597-606.
12. DERRY, J., OCHS, H., and FRANCKE, U. (1994). Isolation of a novel gene mutated in Wiskott-Aldrich syndrome. Cell 78, 635-644.
13. DUPRÉ, L., AIUTI, A., TRIFARI, S., MARTINO, S., SARACCO, P., BORDIGNON, C., and RONCAROLO, M.G. (2002). Wiskott-Aldrich syndrome protein regulates lipid raft dynamics during immunological synapse formation. Immunity 17, 157-166.
14. DUPRÉ, L., TRIFARI, S., FOLLENZI, A., MARANGONI, F., LAIN DE LERA, T., BERNAD, A., MARTINO, S., TSUCHIYA, S., BORDIGNON, C., NALDINI, L., AIUTI, A., and RONCAROLO, M.G. (2004). Lentiviral vector-mediated gene transfer in T cells from Wiskott-Aldrich syndrome patients leads to functional correction. Mol. Ther. 10, 903-915.
15. DUPUIS-GIROD, S., MEDIONI, J., HADDAD, E., QUARTIER, P., CAVAZZANA-CALVO, M., LE DEIST, F., DE SAINT BASILE, G., DELAUNAY, J., SCHWARZ, K., CASANOVA, J., BLANCHE, S., and FISCHER, A. (2003). Autoimmunity in Wiskott-Aldrich syndrome: Risk factors, clinical features, and outcome in a single-center cohort of 55 patients. Pediatrics 111, 622-627.
16. FILIPOVICH, A.H., STONE, J.V., TOMANY, S.C., IRELAND, M., KOLLMAN, C., PELZ, C.J., CASPER, J.T., COWAN, M.J., EDWARDS, J.R., FASTH, A., GALE, R.T., JUNKER, A., KAMANI, N.R., LOECHELT, B.J., PIETRYGA, D.W., RINGDEN, O., VOWELS, M., HEGLAND, J., WILLIAMS, A.V., KLEIN, J.P., SOBOCINSKI, K.A., ROWLINGS, P.A., and HOROWITZ, M.M. (2001). Impact of donor type on outcome of bone marrow transplantation for Wiskott-Aldrich syndrome: Collaborative study of the International Bone Marrow Transplant Registry and the National Marrow Donor Program. Blood 97, 1598-1603.
17. GALLEGO, M.D., SANTAMARIA, M., PENA, J., and MOLINA, I.J. (1997). Defective actin reorganization and polymerization of Wiskott-Aldrich T cells in response to CD3-mediated stimulation. Blood 90, 3089-3097.
18. GISMONDI, A., CIFALDI, L., MAZZA, C., GILIANI, S., PAROLINI, S., MORRONE, S., JACOBELLI, J., BANDIERA, E., NOTARANGELO, L.D., and SANTONI, A. (2004). Impaired natural and CD16-mediated NK cell cytotoxicity in patients with WAS and XLT: Ability of IL-2 to correct NK cell functional defect. Blood 104, 436-443.
19. HACEIN-BEY-ABINA, S., LE DEIST, F., CARLIER, F., BOUNEAUD, C., HUE, C., DE VILLARTAY, J., THRASHER, A.J., WULFFRAAT, N., SORENSEN, R., DUPUIS-GIROD, S., FISCHER, A., DAVIES, E., KUIS, W., LEIVA, L., and CAVAZZANA-CALVO, M. (2002). Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy. N. Engl. J. Med. 346, 1185-1193.
20. HACEIN-BEY-ABINA, S., VON KALLE, C., SCHMIDT, M., LE DEIST, F., WULFFRAAT, N., McINTYRE, E., RADFORD, I., VILLEVAL, J.L., FRASER, C.C., CAVAZZANA-CALVO, M., and FISCHER, A. (2003). A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. N. Engl. J. Med. 348, 255-256.
21. HADDAD, E., ZUGAZA, J.L., LOUACHE, F., DEBILI, N., CROUIN, C., SCHWARZ, K., FISCHER, A., VAINCHENKER, W., and BERTOGLIO, J. (2001). The interaction between Cdc42 and WASP is required for SDF-1-induced T-lymphocyte chemotaxis. Blood 97, 33-38.
22. HIGGS, H., and POLLARD, T. (2000). Activation by Cdc42 and PIP2 of Wiskott-Aldrich syndrome protein (WASp) stimulates actin nucleation by Arp2/3 complex. J. Cell Biol. 150, 117-120.
23. KLEIN, C, NGUYEN, D., LIU, C.H., MIZOGUCHI, A., BHAN, A.K., MIKI, H., TAKENAWA, T., ROSEN, F.S., ALT, F.W., MULLIGAN, R.C., and SNAPPER, S.B. (2003). Gene therapy for Wiskott-Aldrich syndrome: Rescue of T-cell signaling and amelioration of colitis upon transplantation of retrovirally transduced hematopoietic stem cells in mice. Blood 101, 2159-2166.
24. LEVERRIER, Y., LORENZI, R., BLUNDELL, M.P., BRICKELL, P., KINNON, C., RIDLEY, A.J., and THRASHER, A.J. (2001). The Wiskott-Aldrich syndrome protein is required for efficient phagocytosis of apoptotic cells. J. Immunol. 166, 4831-4834.
25. LOGAN, A.C., LUTZKO, C., and KOHN, D.B. (2002). Advances in lentiviral vector design for gene-modification of hematopoietic stem cells. Curr. Opin. Biotechnol. 13, 429-436.
26. MARTIN, F., TOSCANO, M.G., BLUNDELL, M., PRECHA, C., SRIVASTAVA, G.K., SANTAMARIA, M., THRASHER, A.J., and MOLINA, I.J. (2005). Lentiviral vectors transcriptionally targeted to hematopoietic cells by WASP gene proximal promoter sequences. Gene Ther. 12, 715-723.
27. MOLINA, I.J., SANCHO, J., TERHORST, C., ROSEN, F.S., and REMOLD-O'DONNELL, E. (1993). T cells of patients with the Wiskott-Aldrich syndrome have a restricted defect in proliferative responses. J. Immunol. 151, 4383-4390.
28. ORANGE, J.S., HARRIS, K.E., ANDZELM, M.M., VALTER, M.M., GEHA, R.S., and STROMINGER, J.L. (2003). The mature activating natural killer cell immunologic synapse is formed in distinct stages. Proc. Natl. Acad. Sci. U.S.A. 100, 14151-14156.
29. ROHRER, J., and CONLEY, M.E. (1999). Correction of X-linked immunodeficient mice by competitive reconstitution with limiting numbers of normal bone marrow cells. Blood 94, 3358-3365.
30. SHCHERBINA, A., CANDOTTI, F., ROSEN, F.S., and REMOLD-O'DONNELL, E. (2003). High incidence of lymphomas in a sub-group of Wiskott-Aldrich syndrome patients. Br. J. Haematol. 121, 529-530.
31. SNAPPER, S.B., ROSEN, F.S., MIZOGUCHI, E., COHEN, P., KHAN, W., LIU, C.-H., HAGEMANN, T.L., KWAN, S.P., FERRINI, R., DAVIDSON, L., BHAN, A.K., and ALT, F.W. (1998). Wiskott-Aldrich syndrome protein-deficient mice reveal a role for WASP in T but not B cell activation. Immunity 9, 81-91.
32. SNAPPER, S.B., MEELU, P., NGUYEN, D., STOCKTON, B.M., BOZZA, P., ALT, F.W., ROSEN, F.S., VON ANDRIAN, U.H., and KLEIN, C. (2005). WASP deficiency leads to global defects of directed leukocyte migration in vitro and in vivo. J. Leukoc. Biol. 77, 993-998.
33. STROM, T.S., TURNER, S., ANDREANSKY, S., LIU, H., DOHERTY, P.C., SRIVASTAVA, D., CUNNINGHAM, J., and NIENHUIS, A.W. (2003). Defects in T-cell-mediated immunity to influenza virus in murine Wiskott-Aldrich syndrome are corrected by oncoretroviral vector-mediated gene transfer into repopulating hematopoietic cells. Blood 102, 3108-3116.
34. THRASHER, A.J. (2002). WASp in immune-system organization and function. Nat. Rev. Immunol. 2, 635-646.
35. WADA, T., SCHURMAN, S.H., GARABEDIAN, E.K., YACHIE, A., and CANDOTTI, F. (2005). Analysis of T-cell repertoire diversity in Wiskott-Aldrich syndrome. Blood 106, 3895-3897.
36. WISKOTT, A. (1937). Familiarer, angeborener Morbus Werlhofii? Mschr. Kinderheilk. 68, 212-216.
37. ZHANG, J., SHEHABELDIN, A., DA CRUZ, L.A.G., BUTLER, J., SOMANI, A.K., McGAVIN, M., KOZIERADZKI, I., DOS SANTOS, A.O., NAGY, A., GRINSTEIN, S., PENNINGER, J.M., and SIMINOVITCH, K.A. (1999). Antigen receptor-induced activation and cytoskeletal rearrangement are impaired in Wiskott-Aldrich syndrome protein-deficient lymphocytes. J. Exp. Med. 190, 1329-1341.